Gen İlaç Acquires Majority Stake in Brain-Health Startup Neo Auvra
The convergence of pharmaceuticals and digital health is accelerating as Turkish pharmaceutical giant Gen İlaç has taken majority control of Neo Auvra, a startup specializing in AI-powered brain-health technologies. This strategic move underscores the growing importance of tech-driven therapeutic solutions in modern healthcare.
The digital health sector, particularly in specialized areas like brain health, is seeing increased consolidation and strategic investments from traditional healthcare players. This trend is exemplified by Turkish pharmaceutical company Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) taking majority control of Istanbul-based digital health startup Neo Auvra. The acquisition, announced today, sees Gen İlaç increasing its stake to 76.94%, completing a four-year investment journey.
Neo Auvra, founded in 2021 by Bekir Tarcan Kiper and Ömer Kerem Özçakıl, develops advanced brain-health technologies that blend digital medicine and digital therapeutics. Their solutions integrate virtual reality (VR), augmented reality (AR), extended reality (XR), wearable sensors, and biometric measurement to objectively assess cognitive, socio-emotional, and physical conditions. The company's NORA VRx™ Core I platform, a VR-based tool for memory, attention, and problem-solving, is already registered with the US FDA, indicating a readiness for broader market adoption.
Gen İlaç's path to majority ownership began in January 2022 with an initial $1.2 million investment for a 9.09% stake. Subsequent investments, including the conversion of a $700,000 convertible loan and an additional $500,000 share purchase, gradually increased their holding to 35.15% before this latest transaction. This incremental acquisition strategy demonstrates a calculated long-term commitment to Neo Auvra's technology and its potential to reshape neurological care.
This deal highlights a broader industry shift where pharmaceutical companies are looking beyond traditional drug development to integrate digital solutions for enhanced patient outcomes and market reach. By acquiring a controlling interest in Neo Auvra, Gen İlaç gains access to cutting-edge diagnostic and therapeutic tools that can complement its existing product portfolio, offering a more holistic approach to brain health. This positions them favorably in a rapidly evolving healthcare landscape where personalized, technology-driven interventions are becoming paramount.
INTELLIGENCE BRIEF
WHY IT MATTERS
This acquisition signals a critical shift in the healthcare industry, where pharmaceutical companies are increasingly recognizing the value of integrating digital therapeutics and AI-powered solutions. It validates the potential of startups like Neo Auvra to offer innovative, measurable interventions for complex health conditions, moving beyond traditional drug-centric models. The deal sets a precedent for further convergence between pharma and tech in Turkey and beyond.
WHO IS INVOLVED
Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), Neo Auvra, Bekir Tarcan Kiper (Co-founder, Neo Auvra), Ömer Kerem Özçakıl (Co-founder, Neo Auvra).
MARKET IMPACT
The deal underscores the growing trend of pharmaceutical companies venturing into digital health to diversify their offerings and address unmet patient needs with technology. It highlights the increasing strategic value of digital therapeutics, especially those leveraging advanced technologies like VR and AI for objective health assessment and intervention. This could spur more M&A activity in the digital health and medtech sectors.
This story was drafted with AI assistance and reviewed by VC Think editors before publication. Facts, figures, and names may be inaccurate — verify important details independently.
AI Coding Assistant 'OpenCode' Gains Momentum as Open-Source Alternative
Read
Mistral AI Secures Record $3.5 Billion Series D Funding, Valued at $24 Billion
Read